Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5459 in Relapsed or Refractory Multiple Myeloma
NCT04083534Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vonsetamig in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Sep 2019; status: completed.
02
Drugs
vonsetamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04083534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083534.